- Home
- IMRN vs AEON Comparison
IMRN vs AEON Comparison
Compare IMRN & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- AEON
- Stock Information
- Founded
- IMRN 1994
- AEON N/A
- Country
- IMRN Australia
- AEON United States
- Employees
- IMRN N/A
- AEON N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- AEON Health Care
- Exchange
- IMRN Nasdaq
- AEON Nasdaq
- Market Cap
- IMRN 14.4M
- AEON 13.5M
- IPO Year
- IMRN N/A
- AEON N/A
- Fundamental
- Price
- IMRN $2.10
- AEON $0.88
- Analyst Decision
- IMRN
- AEON Strong Buy
- Analyst Count
- IMRN 0
- AEON 1
- Target Price
- IMRN N/A
- AEON $7.20
- AVG Volume (30 Days)
- IMRN 96.3K
- AEON 407.6K
- Earning Date
- IMRN 08-29-2025
- AEON 11-12-2025
- Dividend Yield
- IMRN N/A
- AEON N/A
- EPS Growth
- IMRN N/A
- AEON N/A
- EPS
- IMRN N/A
- AEON N/A
- Revenue
- IMRN $4,777,422.00
- AEON N/A
- Revenue This Year
- IMRN N/A
- AEON N/A
- Revenue Next Year
- IMRN N/A
- AEON N/A
- P/E Ratio
- IMRN N/A
- AEON N/A
- Revenue Growth
- IMRN 48.63
- AEON N/A
- 52 Week Low
- IMRN $1.50
- AEON $0.38
- 52 Week High
- IMRN $2.48
- AEON $73.44
- Technical
- Relative Strength Index (RSI)
- IMRN 50.56
- AEON 45.76
- Support Level
- IMRN $2.10
- AEON $0.88
- Resistance Level
- IMRN $2.24
- AEON $0.96
- Average True Range (ATR)
- IMRN 0.12
- AEON 0.16
- MACD
- IMRN -0.02
- AEON -0.03
- Stochastic Oscillator
- IMRN 32.50
- AEON 3.61
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.